Recon: How Trump and RFK Jr. could reshape healthcare; Moderna reports slower RSV vaccine sales but better-than-expected COVID vaccine revenue

• ‘MAHA’ is moving into Trump’s White House. Here’s who RFK Jr. could bring along for the ride (STAT)
• D.C. Diagnosis: RFK Jr. targets the F in FDA (STAT)
• RFK Jr. says ‘entire departments’ at FDA ‘have to go’ (The Hill) (MSNBC interview)
• Donald Trump returns to the presidency with big ambitions to shake up health care (STAT)
• Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry (STAT) (MedTech Dive)
• FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy (Endpoints)
• Moderna reports slow start to RSV sales as Bancel steps back from commercial role (Endpoints)
• Moderna reports surprise profit on higher-than-expected COVID vaccine sales (Reuters)

• AstraZeneca says China has detained a senior executive (STAT)
• Coherus restarts biosimilar supply after delays; Novavax ends Covid vaccine deal with UK (Endpoints)
• Africa health body calls on Trump to honour US vaccine pledges (Reuters)
• Whirlwind Week As German Medtechs Ponder Trump Effect And Whither Domestic Government (MedTech Insight)
• UK Diagnostic Services Must Get In Shape To Benefit From AI Opportunities (MedTech Insight)

• Sarepta discontinues next-generation Duchenne drugs (STAT)
• Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact (Endpoints)
• Denali teases early data for enzyme replacement therapy in rare disease (Endpoints)
• Xanax maker Viatris beats quarterly estimates on demand for new generic drugs (Reuters)
• Genmab chops early cancer prospects to prioritize Phase 3 projects (Endpoints)
• Aurinia cuts nearly half of its workforce in second round of layoffs this year (Endpoints)
• Geron’s royalty deal; Minghui’s new VEGF bispecific data (Endpoints)
• Grifols on track to meet 2024 targets as core earnings rise (Reuters)
• Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit (Fierce Pharma)
• AGC Biologics aims to become 'safe harbor' for manufacturing clients as new CEO takes the reins (Fierce Pharma)
• While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing (BioSpace)
• Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization (BioSpace)

• These 6 companies are using AI to streamline clinical trials for pharma (STAT)
• How Menlo Ventures thinks AI in health tech is going to be commoditized (Endpoints)
• US FDA approves Johnson & Johnson's device for heart condition (Reuters)
• Tempus AI to buy genetic testing company for $600M (MedTech Dive)
• Masimo, amid leadership transition, targets cost reductions (MedTech Dive)
• Advamed asks CMS to cover extra imaging of dense breast tissue (MedTech Dive)
• lucoModicum’s Magnetohydrodynamic CGM Platform Moves Closer To The Clinic (MedTech Insight)

• Social media misinformation is scaring women about birth control (STAT)
• Cover Supplemental Breast Screenings, AdvaMed Urges Medicare (MedTech Insight)
• While the Orphan Battles Wage, Jazz Takes a Loss (FDA Law Blog)
• Siemens Healthineers confident it can cope with Trump tariffs (MedTech Dive)